Uric Acid Reduction Therapy

Uric acid reduction therapy employs allopurinol, febuxostat, or uricosuric agents controlling hyperuricemia preventing gout and renal damage. Xanthine oxidase inhibition reduces uric acid production. Uricase administration enzymatically degrades circulating uric acid. Uricosuric agents increase renal excretion. Combination therapy optimises urate control.

Urate monitoring guides dose titration. Acute gout attack prevention employs colchicine during initiation. Renal function monitoring assesses kidney protection. Regulatory submissions justify mechanism selections. Post-approval surveillance identifies safety patterns.